The OlympiA Trial
May 03, 2016
Dr. Charles E. Geyer, Professor of Medicine and Harrigan, Haw, Luck Families Chair in Cancer Research at the Virginia Commonwealth University, Massey Cancer Center describes the OlympiA trial. OlympiA is the first clinical trial for people with a BRCA1 or BRCA2 mutation who have been recently diagnosed with stage 2 or stage 3 breast cancer. The study will evaluate whether the PARP inhibitor olaparib is safe and improves outcomes.
People concerned about hereditary cancer, cancer survivors, previvors, and health care providers.